Abstract
Busulfan is an alkylating agent commonly used in preparative regimens for hematopoietic stem cell transplant (HSCT). Early clinical trials, prior to the use of seizure prophylaxis, revealed a high degree of neurotoxicity associated with myeloablative doses of this agent. Phenytoin has been widely used as seizure prophylaxis with busulfan. However, potential concerns with its use include the length of time to achieve a therapeutic steady state, risk of hepatotoxicity, and drug-drug interactions with busulfan and other agents used during conditioning.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
